As mentioned earlier, p53 activation through acetylation caused by SIRT1 inhibition diminished the number of CML LSCs when the SIRT1 inhibitor was used in combination with a TKI53. Here, SIRT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.